Exabis Library
Welcome to the e-CCO Library!
P554: Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P554: Vedolizumab Associated quality of Life and inflammatory bowel disease control Upon Entering a subcutaneous switching program (VALUE) – Results from a multi-centre UK study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P555 Frequent disease relapse after withdrawal of infliximab in IBD patients with sustained remission
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P555: Coagulation disorders in a population of patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P555: Deep remission and mucosal healing in IBD patients under immunosuppression with azathioprine and 6-mercaptopurine
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P555: Outcomes of multiswitching from original infliximab to biosimilars in patients with inflammatory bowel disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P555: Systematic review of interventions for chronic abdominal pain management in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P555: Systematic review with meta-analysis: The impact of cancer treatments on the disease activity of inflammatory bowel diseases
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P555: Ustekinumab tissue and serum levels in patients with Crohn’s disease are closely correlated though not consistently associated with objective response after induction.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P556 Long-term probability of retreatment with anti-TNF therapy after discontinuation based on mucosal healing in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P556: Cyclosporine in acute severe steroid-refractory ulcerative colitis: Short-and long-term outcomes
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P556: Female Crohn's disease patients and ulcerative colitis patients on biologic therapy are most disabled
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P556: Safety and efficacy of ustekinumab in the treatment of Crohn's Disease: A systematic review and meta-analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P556: Surgery in high-risk paediatric Crohn's Disease treated with up-front anti-TNF agents and long-standing biologic therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P556: The effect of multiple doses of upadacitinib 45 mg on the pharmacokinetics of cytochrome P450 substrates in healthy adult subjects
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P556: The prevalence of metabolic bone disease in patients with IBD- preliminary results from POLIBD study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P557 Increased risk of anastomotic leak in Crohn’s disease patients unable to complete preoperative mechanical bowel preparation
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P557: Analysis of colectomy rates and advanced therapy prescribing for ulcerative colitis in Lothian; Scotland an updated population based cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P557: Cost-effectiveness of infliximab vs. surgery for severe chronic ulcerative colitis: a Markov analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P557: Long-term outcomes following laparoscopic ileocecal resection without any residual lesion for Crohn’s disease: a single-center observational study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM